UPJOHN DERACYN FOR PANIC DISORDER NEEDS LONGER CLINICAL TRIALS, POSSIBLE COMBINING OF ENDPOINTS, FDA CMTE. SUGGESTS; EFFICACY DATA FOUND INSUFFICIENT
Executive Summary
Upjohn should consider conducting clinical trials of longer duration and possibly look at a combination of endpoints for its Deracyn drug for panic disorder, FDA's Psychopharmacologic Drugs Advisory Committee decided April 25 at its meeting in Rockville, Md.